Evidence map›Paper›PMID 27256705›Full record

ArticleClinical pharmacology and therapeutics2016

Genomewide Association Studies in Pharmacogenomics: Meeting Report of the NIH Pharmacogenomics Research Network-RIKEN (PGRN-RIKEN) Collaboration.

S W Yee, Y Momozawa, Y Kamatani, R F Tyndale, R M Weinshilboum, M J Ratain, K M Giacomini, M Kubo

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical pharmacology and therapeutics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Genomewide Association Studies in Pharmacogenomics.Clinical pharmacology and therapeutics · 2021
    Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

S W YeeUniversity of California San Francisco, Department of Bioengineering and Therapeutic Sciences, San Francisco, California, USA.
Y MomozawaUniversity of California San Francisco, Department of Bioengineering and Therapeutic Sciences, San Francisco, California, USA.
Y KamataniUniversity of California San Francisco, Department of Bioengineering and Therapeutic Sciences, San Francisco, California, USA.
R F TyndaleUniversity of California San Francisco, Department of Bioengineering and Therapeutic Sciences, San Francisco, California, USA.
R M WeinshilboumUniversity of California San Francisco, Department of Bioengineering and Therapeutic Sciences, San Francisco, California, USA.
M J RatainUniversity of California San Francisco, Department of Bioengineering and Therapeutic Sciences, San Francisco, California, USA.
K M GiacominiUniversity of California San Francisco, Department of Bioengineering and Therapeutic Sciences, San Francisco, California, USA. kathy.giacomini@ucsf.edu.
M KuboUniversity of California San Francisco, Department of Bioengineering and Therapeutic Sciences, San Francisco, California, USA. michiaki.kubo@riken.jp.

Funding

Pharmacogenomics of Membrane TransportersU19GM061390 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI KWOK, PUI-YAN · 2010 to 2014
$16.3M
PGRN Administrative Coordination Hub, ACH (PGRN)U24GM115370 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GIACOMINI, KATHLEEN M, JOHNSON, GRAHAM T. · 2015 to 2019
$2.7M
NIGMS NIH HHS U19 GM061390NIGMS NIH HHS U24 GM115370
6 · The paper itself

Abstract

Genomewide association studies (GWAS) have resulted in the identification of many heritable genetic factors that underlie risk for human disease or variation in physiologic traits. In contrast, there are fewer GWAS of drug response phenotypes, despite extensive unexplained interindividual variability. To address this urgent need, the NIH Pharmacogenomics Research Network (PGRN) and the Center for Integrative Medical Sciences (IMS) at RIKEN support a collaboration, PGRN-RIKEN, with the goal of accelerating GWAS of drug response phenotypes.

Indexed as

Intersectoral CollaborationGenome-Wide Association StudyHumansPharmacogenetics

Identifiers

PMID27256705
PMCPMC5056156

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.